Johnson & Johnson today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.
In building this facility, Johnson & Johnson will continue investing in advanced manufacturing processes and in training to develop a workforce skilled in advanced technologies. It will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.
“Pennsylvania is a powerhouse for innovation and manufacturing in the life sciences,” said Pennsylvania Governor Josh Shapiro in a statement. “Just a few years ago we weren’t even on the field - but today we’re competing and winning. We’ve done it by creating the first economic development plan for Pennsylvania in 2 decades, and following through on it by cutting red tape, making strategic investments in key industries like the life sciences, and strengthening our workforce. That’s why companies like Johnson & Johnson are choosing to double down on their investments here in our Commonwealth - because they know we’ve got the strategy, the workforce, and the speed they need to succeed.”
J&J has 10 Pennsylvania facilities encompassing more than 2 million square feet dedicated to manufacturing, research, distribution, and office operations.
The announcement is part of the company’s previously announced $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029.
